345 related articles for article (PubMed ID: 20702855)
1. Coupled for cross-presentation in tumor immunotherapy.
Pang B; Neefjes J
Sci Transl Med; 2010 Aug; 2(44):44ps40. PubMed ID: 20702855
[TBL] [Abstract][Full Text] [Related]
2. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
3. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
4. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
5. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.
van der Most RG; Currie A; Robinson BW; Lake RA
Cancer Res; 2006 Jan; 66(2):601-4. PubMed ID: 16423984
[TBL] [Abstract][Full Text] [Related]
6. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
7. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
Tacken PJ; de Vries IJ; Torensma R; Figdor CG
Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells for specific cancer immunotherapy.
Meidenbauer N; Andreesen R; Mackensen A
Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells as vectors for immunotherapy of cancer.
Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK
Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-based cancer immunotherapies.
Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathological approaches to human tumor immunology.
Sato N; Hirohashi Y; Tsukahara T; Kikuchi T; Sahara H; Kamiguchi K; Ichimiya S; Tamura Y; Torigoe T
Pathol Int; 2009 Apr; 59(4):205-17. PubMed ID: 19351363
[TBL] [Abstract][Full Text] [Related]
13. Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation.
Chhabra A; Mehrotra S; Chakraborty NG; Mukherji B; Dorsky DI
Eur J Immunol; 2004 Oct; 34(10):2824-33. PubMed ID: 15368298
[TBL] [Abstract][Full Text] [Related]
14. Processing and presentation of tumor antigens and vaccination strategies.
van der Bruggen P; Van den Eynde BJ
Curr Opin Immunol; 2006 Feb; 18(1):98-104. PubMed ID: 16343880
[TBL] [Abstract][Full Text] [Related]
15. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects].
Rossowska J; Pajtasz-Piasecka E
Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967
[TBL] [Abstract][Full Text] [Related]
16. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.
Cannon MJ; O'Brien TJ; Underwood LJ; Crew MD; Bondurant KL; Santin AD
Expert Rev Anticancer Ther; 2002 Feb; 2(1):97-105. PubMed ID: 12113075
[TBL] [Abstract][Full Text] [Related]
17. Dendritic Cells and Cancer Immunity.
Gardner A; Ruffell B
Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
[TBL] [Abstract][Full Text] [Related]
18. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity.
Saccheri F; Pozzi C; Avogadri F; Barozzi S; Faretta M; Fusi P; Rescigno M
Sci Transl Med; 2010 Aug; 2(44):44ra57. PubMed ID: 20702856
[TBL] [Abstract][Full Text] [Related]
19. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer].
Punt CJ; de Vries IJ; Mulders PF; Adema GJ; Figdor CG
Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2408-14. PubMed ID: 10608974
[TBL] [Abstract][Full Text] [Related]
20. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
